# Archon Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/archon-biosciences

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.archon.bio/
- Total disclosed funding: $20M
- Latest round: Series A (May 30, 2023)
- Investors on record: 7

## About

Based in Washington, US, Archon Biosciences, Inc. specializes in developing advanced protein therapeutics called antibody cages (AbCs), targeting complex disease pathways to improve treatment outcomes in areas like oncology and autoimmune disorders. In October 2024, Archon Biosciences, Inc. raised USD 20 million in seed funding led by Madrona Venture Group, with participation from DUMAC, Sahsen Foundation, WRF Capital, Pack Ventures, Alexandria Venture Investments, and Cornucopian Capital.

The company provides a wide range of biotechnology products, such as antibody cages (AbCs), which combine AI-driven design and structural engineering to optimize antibody distribution, binding affinity, and target engagement. These therapeutics are engineered for applications that require precise control over size, shape, and function to address diseases that traditional therapies cannot reach. Additionally, the firm also provides solutions in generative protein design and Fc-based biologics for advanced drug development. Archon Biosciences targets markets primarily in North America and Europe.

Archon Biosciences operates on a model that emphasizes partnerships and collaborations with pharmaceutical companies and research institutions. The company’s flagship antibody cage platform, recognized for its approach to biologics, serves as the cornerstone of these collaborations. Transactions are structured around B2B relationships, wherein clients may engage in research and development partnerships to leverage Archon's technological capabilities for their therapeutic pipelines.

In October 2024, Archon Biosciences, Inc. raised USD 20.00 million in seed funding, which will be utilized to support the development of its product aimed at treating cancer and other illnesses. The company plans to introduce new products targeting these therapeutic areas and aims to expand into additional markets globally, particularly focusing on regions in Asia and further into Europe by 2025.

## Funding rounds

- Series A, May 30, 2023, $20M — Alexandria Venture Investments, Madrona Venture Group, WRF Capital, DUMAC, Sahsen Foundation, Pack Ventures, Cornucopian Capital

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Madrona Venture Group (https://capitalatlas.ai/funds/madrona-venture-group) — Series A
- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series A
- DUMAC — Series A
- Sahsen Foundation — Series A
- Pack Ventures (https://capitalatlas.ai/funds/pack-ventures) — Series A
- Cornucopian Capital (https://capitalatlas.ai/funds/cornucopian-capital) — Series A